Clinical Trials Browser

Biliary Tract Neoplasms

Carcinoma, Hepatocellular

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular

Liver Neoplasms

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

Biliary Tract Neoplasms, Cholangiocarcinoma

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma

Biliary Tract Neoplasms, Carcinoma, Hepatocellular

Carcinoma, Hepatocellular, Liver Neoplasms

Advanced Gastric Adenocarcinoma

Carcinoma, Hepatocellular

Carcinoma, Hepatocellular

Biliary Tract Neoplasms

Biliary Tract Neoplasms Immunotherapy

Carcinoma, Hepatocellular

Stomach Neoplasms

Pancreatic Neoplasms

Carcinoma, Hepatocellular

Carcinoma, Hepatocellular

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma

Biliary Tract Tumors

Carcinoma, Hepatocellular

Cholangiocarcinoma

Stomach Neoplasms

Carcinoma, Hepatocellular, Recurrence

Carcinoma, Hepatocellular

Cholangiocarcinoma

Carcinoma, Hepatocellular, Liver Neoplasms

Carcinoma, Hepatocellular

Carcinoma, Hepatocellular

Cholangiocarcinoma

Cholangiocarcinoma

Carcinoma, Hepatocellular

Cholangiocarcinoma

Carcinoma, Hepatocellular

Carcinoma, Hepatocellular

Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Carcinoma, Hepatocellular

Carcinoma, Hepatocellular

Cholangiocarcinoma

Carcinoma, Hepatocellular, Liver Neoplasms

Cholangiocarcinoma

Carcinoma, Hepatocellular

Carcinoma, Hepatocellular, Liver Diseases

Carcinoma, Hepatocellular, Liver Diseases

Carcinoma, Hepatocellular

Cholangiocarcinoma

Cholangiocarcinoma

Carcinoma, Hepatocellular

Carcinoma, Hepatocellular

Clinical Trials

Phase II Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Albumin-Bound Paclitaxel and Lenvatinib as Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer

SLIDE-HCC

Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)

MK-3475-06B

Investigation of Predictive Biomarkers in Patients With Advanced BTC Treated With Lenvatinib Plus Pembrolizumab

HAIC-quad

Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer

A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma

Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma

TREMENDOUS-2

Multimodal Deep Learning for Postoperative Liver Cancer Risk Stratification and Intervention

An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy.

Pembrolizumab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer

ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC

Lenvatinib in Combination With Nivolumab Plus Chemotherapy in Metastatic Gastric Cancer Patients With Malignant Ascites

Lenvatinib and Pembrolizumab Maintenance Therapy for the Treatment of Patients of Advanced Unresectable Pancreatic Cancer

Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer

TACE Combined With Lenvatinib and PD-1 Inhibitor for Ruptured Hepatocellular Carcinoma

CASTLE-ZS-02

Spring

LEAF-01

D-TACE-HAIC Combined With Envafolimab and Lenvatinib for Unresectable ICC

Lenvatinib Plus Tislelizumab and CapeOX as First-Line Treatment for Advanced GC/GEJC With Positive PD-L1 and Low TMEscore

Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model

Lenvatinib Plus SIRT vs Lenvatinib in TACE-Refractory HCC

Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study

CCGLC-001

Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC

A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma

Neoadjuvant Therapy of HAIC（GEMOX） Combined With Adebrelimab and Lenvatinib for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors

Lenvatinib Plus Sintilimab in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Liver Cancer

Lenvatinib Combined with Tislelizumab and TACE Applied As Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma with High-risk Recurrence Factors

Lenvatinib, Tislelizumab Plus Gemcitabine and Cisplatin (GPLET) in Patients with Advanced Cholangiocarcinoma

HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma

TIPS Combined With Lenvatinib and PD-1 Inhibitor for Advanced HCC With Main Trunk PVTT

Second-line Treatment With Serplulimab, Lenvatinib, and Paclitaxel in Advanced Gastric Cancer After Prior Immunotherapy

Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant

CCGLC-011

GEMOX Combined With Targeted Therapy and Immunotherapy for Patients With Advanced Cholangiocarcinoma

PRIMER-1

CCGLC-013

Triple Therapy for Intermediate-advanced HCC With BDTT (TALENP002)

bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC

bTAE-HAIC Combined With Lenvatinib and Sintilimab for Infiltrative Hepatocellular Carcinoma

Ablation in Combination With Lenvatinib and Anti-PD-1 Antibodies

GEMOX-HAIC Plus GEM-SYS in Combination With Lenvatinib and PD-1 Inhibitor for Large Unresectable ICC

Combined Therapy Using Gemcitabine and Cisplatin Chemotherapy, Lenvatinib and Adebrelimab for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma

Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors

CCGLC-008